Thermo Fisher Scientific and UC Davis Launch Center of Excellence in Clinical Metabolomics

- Thermo Fisher Scientific, (NYSE: TMO) the world leader in serving science, and the University of California, Davis (UC Davis) West Coast Metabolomics Center today announced The Center of Excellence in Clinical Metabolomics, a research collaboration to provide the metabolomics community with innovations, best practices and standard operating procedures to support the rapid scale-up of large cohort studies and clinical research.

A scientist operates a Thermo Scientific Vanquish UHPLC with Q-Exactive HF-X mass spectrometer used in metabolomics research.

Metabolomics is an increasingly important field where researchers identify diagnostic biomarkers for disease, discover new drug targets, develop tools to predict drug response, and enable precision medicine overall. Advancements in this area can help ensure that patients receive more targeted medicines and increase the likelihood those therapies will achieve their intended outcomes.

The Center of Excellence in Clinical Metabolomics, based on the UC Davis Sacramento campus, will enable targeted and untargeted metabolic profiling for large-scale population-based cohorts across translational research and precision medicine. The Center will develop standardized processes for the research community, including end-to-end metabolic profiling workflows; optimized liquid chromatography-mass spectrometry (LC-MS) methods, protocols for analytical controls to monitor instrument performance; and training courses for metabolomics staff, scientists and core lab managers.

"The progress we've made in the areas of vaccines and therapy development during the pandemic would have been impossible without ongoing commitments to invest in and share new scientific techniques, and this underscores the importance of our collaboration with UC Davis," said Mark Stevenson , executive vice president and chief operating officer of Thermo Fisher. "The work we'll do here serves science by refining basic, but critical scientific techniques for metabolomics so they can quickly become clinically relevant."

As part of the collaboration, Thermo Fisher is providing its powerful Orbitrap technology . The Center will generate high-quality data using the latest generation of Orbitrap-based mass spectrometers in conjunction with the Thermo Scientific Vanquish Duo UHPLC system for increased throughput. This instrument combination will support the development of streamlined workflows for large-scale studies and translational research.

"We aim to provide advance training courses for early career community members as well as independent investigators and scientists, and this will be supported by state-of-the-art technology from Thermo Fisher ," said Oliver Fiehn , director, West Coast Metabolomics Center at the UC Davis Genome Center. "This collaboration will drive the creation of innovative analytical approaches for both untargeted and targeted applications providing the metabolomics community with advanced methodologies for their vital work."

For more information, please visit www.metabolomics.ucdavis.edu/clinical-metabolomics

About UC Davis West Coast Metabolomics Center
Since 2004, the UC Davis West Coast Metabolomics Center is an international leader in metabolomics research, service and education. The Center combines four metabolomic research laboratories with a large service core, training courses, seminars and workshops. We provide opportunities for research collaborations but also make general fee-based services available to biomedical, preclinical and clinical researchers, including industry investigators. We advance the state-of-the art in mass spectrometry-based metabolomics research, specifically in computational metabolomics. The Center hosts MassBank.us and a wide range of other tools and data repositories for freely available downloads. For more information, please visit www.metabolomics.ucdavis.edu

About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue exceeding $30 billion . Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, improving patient diagnostics and therapies or increasing productivity in their laboratories, we are here to support them. Our global team of more than 80,000 colleagues delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services and Patheon. For more information, please visit www.thermofisher.com .

Media Contact Information:
Ron O'Brien
Phone: 781-622-1242
E-mail: ron.obrien@thermofisher.com

Investor Contact Information:
Rafael Tejada
Phone: 781-622-1356
E-mail: rafael.tejada@thermofisher.com

Thermo Fisher Scientific logo (PRNewsfoto/Thermo Fisher Scientific)

Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/thermo-fisher-scientific-and-uc-davis-launch-center-of-excellence-in-clinical-metabolomics-301326475.html

SOURCE Thermo Fisher Scientific

News Provided by PR Newswire via QuoteMedia

The Conversation (0)

Bausch Health to Announce First-Quarter 2024 Results on May 2

Bausch Health Companies Inc. (NYSE:NHC)(TSX:BHC) will release first-quarter 2024 financial results on Thursday, May 2, 2024. Bausch Health will host a conference call and live webcast at 8:00 a.m. U.S. EST to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch Health website prior to the start of the call

Conference Call Details

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less

Court of Appeals for the Federal Circuit Issues Ruling in Norwich Case that Prevents FDA Approval of Norwich's Abbreviated New Drug Application Until 2029

Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), and its gastroenterology business Salix Pharmaceuticals, today announced that the U.S. Court of Appeals for the Federal Circuit in the matter of Salix Pharmaceuticals, LTD. et al v. Norwich Pharmaceuticals, Inc., affirmed the May 17, 2023 decision of the U.S. District Court for the District of Delaware that had denied Norwich Pharmaceuticals, Inc.'s motion for modification of the court's final order preventing the U.S. Food and Drug Administration (FDA) from approving its abbreviated new drug application (ANDA) for XIFAXAN (rifaximin) 550 mg before Oct. 2, 2029. The Court of Appeals also affirmed the August 10, 2022 decision of the District Court that invalidated certain U.S. Patents protecting the composition and use of XIFAXAN® for treating IBS-D. As a result of the Federal Circuit's decision, Norwich's abbreviated new drug application for XIFAXAN (rifaximin) 550 mg remains barred from approval by the U.S. Food and Drug Administration until Oct. 2, 2029

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less

Acne Vulgaris Treatment PrARAZLO Now Available to Patients Through British Columbia PharmaCare Public Drug Plan

Bausch Health, Canada Inc., part of Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), today announced that its topical prescription treatment for acne vulgaris, PrARAZLOTM (tazarotene lotion, 0.045% ww), is now available to patients through BC PharmaCare, the public drug program of British Columbia

ARAZLO is the only tazarotene lotion treatment approved by Health Canada for the topical treatment of acne vulgaris in patients 10 years of age and older.1 The listing by BC PharmaCare means ARAZLO is now available to patients on all public drug plans across Canada.

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less
Cleo Diagnostics

CLEO Appoints CRO to Manage U.S. Ovarian Cancer Clinical Trials

Ovarian cancer diagnostics company, Cleo Diagnostics Limited (ASX:COV) (CLEO, or the Company) is pleased to announce the appointment of international Contract Research Organization (CRO), Lindus Health, as a key partner for its U.S. clinical trials program.

Keep reading...Show less

Medtronic unveils the future of AI in GI: Genius Summit 2024 reveals innovations and collaborations that advance endoscopic care

AI-driven solutions and strategic alliances showcase Medtronic's promise to enhance the efficiency and effectiveness of endoscopy

Medtronic plc (NYSE: MDT), a global leader in healthcare technology, announced the latest advancements in artificial intelligence (AI) for endoscopic care by unveiling ColonPRO™, the latest generation software for the GI Genius™ intelligent endoscopy system, along with a strategic collaboration designed to enhance patient care.

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

Knight to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference

Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a leading pan-American (ex-US) specialty pharmaceutical company, announced today that Samira Sakhia, President and Chief Executive Officer, is scheduled to present a corporate update at the Bloom Burton & Co. Healthcare Investor Conference on Tuesday, April 16, 2024, at 10:30 a.m. ET at the Metro Toronto Convention Centre in Toronto. A copy of the presentation will be available at www.knighttx.com .

About Knight Therapeutics Inc.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
{{ sections }}

Latest Press Releases

Related News

×